Investigational Site Number 840026 — Omaha, Nebraska

Investigational Site Number 840026 is a clinical research site located in Omaha, Nebraska, United States 68114.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

Investigational Site Number 840026 has participated in 2 clinical trials.

Therapeutic areas: Type 1 Diabetes Mellitus, Prostate Cancer Metastatic.

Sponsors: Sanofi.

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Investigational Site Number 840026?

Investigational Site Number 840026 has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Investigational Site Number 840026 conducted?

Investigational Site Number 840026 has 2 clinical trials on record. Their work covers Type 1 Diabetes Mellitus, Prostate Cancer Metastatic.

Is Investigational Site Number 840026 accredited by Crixeo Health?

Investigational Site Number 840026 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Investigational Site Number 840026?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.